Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. We generated an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b...

Descripción completa

Detalles Bibliográficos
Autores principales: Furey, Colleen, Ye, Naiqing, Kercher, Lisa, DeBeauchamp, Jennifer, Crumpton, Jeri Carol, Jeevan, Trushar, Patton, Christopher, Franks, John, Alameh, Mohamad-Gabriel, Fan, Steven H.Y., Phan, Anthony T., Hunter, Christopher A., Webby, Richard J., Weissman, Drew, Hensley, Scott E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168367/
https://www.ncbi.nlm.nih.gov/pubmed/37162920
http://dx.doi.org/10.1101/2023.04.30.538854
Descripción
Sumario:Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. We generated an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b H5 isolate. We show that the vaccine is immunogenic in mice and ferrets and prevents morbidity and mortality of ferrets following 2.3.4.4b H5N1 challenge.

Ejemplares similares